Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 29:16:1287-1295.
doi: 10.2147/JAA.S424152. eCollection 2023.

Multiple Biologics for Multiple T2 Diseases: A Pharmacoepidemiological Algorithm for Sorting Out Patients by Indication

Jeremy Charriot  1 , Vincent Descamps  2 , Roger Jankowski  3 , Milka Maravic  4   5 , Arnaud Bourdin  1
Affiliations

Multiple Biologics for Multiple T2 Diseases: A Pharmacoepidemiological Algorithm for Sorting Out Patients by Indication

Jeremy Charriot et al. J Asthma Allergy. .

Abstract

Background: Several biologics (Bx) and targeted synthetic drugs (TSD) exist to treat T2 diseases, including chronic spontaneous urticaria (CSU), severe asthma (SA), chronic rhinosinusitis with nasal polyposis (CRSwNP) or atopic dermatitis (AD).

Objective: To identify patients treated with Bx/TSD from a dynamic dispensing database using an algorithm-based methodology.

Methods: We used the LRx database (Lifelink Treatment dynamics, IQVIA) which covers nearly 45% of the French retail pharmacies. Patients who had at least one Bx/TSD dispensing from April 2021 to March 2022 were included. An algorithm was designed to determine the indication of the Bx/TSD prescription analyzing all previous drug dispensation since March 2012 following a 3-steps procedure.

Results: A total of 21,677 patients received at least one Bx/TSD between March 2021 and April 2022. The algorithm identified 91.7% (n = 19,884) patients with a T2 disease (AD = 18.4%, CRSwNP = 1.5%, SA = 59.5%, and CSU = 12.4%), the rest having either an association of diseases (1%) or an undetermined one (7.3%). SA was the main reason for Bx/TSD initiation (52%), followed by AD (29%), CSU (14%) and CRSwNP (5%). For SA patients already under biologic at entry, omalizumab was the most frequently prescribed (48%) followed by benralizumab, mepolizumab (22% each) and dupilumab (8%). Dupilumab was mostly prescribed for AD patients (89% for patient-initiated vs 96% for patient-renewed) followed by baricitinib.

Conclusion: The algorithm was able to identify patients with T2 diseases under Bx/TSD treatments. This tool may help to follow the evolution of prescription patterns in the future.

Keywords: T2 diseases; atopic dermatitis; biologics; nasal polyposis; severe asthma; urticaria.

PubMed Disclaimer

Conflict of interest statement

A.B. received payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events from AstraZeneca, GSK, Sanofi, Chiesi, Regeneron, ABScience, Novartis, and was principal investigator in clinical trials for AstraZenaca, GSK and Boehringer Ingelheim. J.C. received payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events from AstraZeneca, GSK, Sanofi, Chiesi. V.D. received payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events from ABBVIE, Janssen, Lilly, Novartis and Sanofi. R.J. reports personal fees from IQVIA, during the conduct of the study; personal fees from Sanofi, outside the submitted work. M.M is affiliated with IQVIA. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
An algorithm constructed using consecutive steps including a scoring model and considering a maximum of 10-years historical dispense data.
Figure 2
Figure 2
Age-classes distribution of patients under Bx/TSD.
Figure 3
Figure 3
Focus on the frequency of oral corticosteroids in patient classified in one disease under Bx/TSD during the period of interest.
See this image and copyright information in PMC

References

    1. Scadding GK, Scadding GW. Innate and adaptive immunity: ILC2 and Th2 cells in upper and lower airway allergic diseases. J Allergy Clin Immunol Pract. 2021;9:1851–1857. - PubMed
    1. Maspero J, Adir Y, Al-Ahmad M, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576–02021. doi: 10.1183/23120541.00576-2021 - DOI - PMC - PubMed
    1. Brusselle GG, Koppelman GH, Taichman DB. Biologic therapies for severe asthma. Taichman DB, editor. N Engl J Med. 2022;386(2):157–171. doi: 10.1056/NEJMra2032506 - DOI - PubMed
    1. Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149:1309–1317.e12. - PubMed
    1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi: 10.1016/S0140-6736(19)31881-1 - DOI - PubMed